3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
25
Stomach Neoplasms
9
Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Hodgkin Disease
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Uveal Melanoma
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Recurrence
2
Mesothelioma, Malignant
2
Lymphoma, B-Cell
2
Leukemia, Myeloid, Acute
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Merkel Cell
2
Carcinoma
2
Brain Neoplasms
2
Interventions
Amifostine
4
Cisplatin
3
Voriconazole
2
Radiotherapy
2
Paclitaxel
2
Methotrexate
2
Drug Therapy
2
selinexor
1
sargramostim
1
pazopanib
1
lometrexol
1
icotinib
1
glucarpidase
1
camrelizumab
1
bismuth tripotassium dicitrate
1
apatinib
1
Telbivudine
1
Surgical Procedures, Operative
1
Pregabalin
1
Pharmaceutical Preparations
1
Ofloxacin
1
Nivolumab
1
Metronidazole
1
Levofloxacin
1
Imatinib Mesylate
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Folic Acid
1
Etoposide
1
Esomeprazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Drug-Related Side Effects and Adverse Reactions
×
Nivolumab
×
Clear all
NCT03638375
2023-12-12
ACTME
Leiden University Medical Center
Phase 1/2
Unknown
34 enrolled